FibroBiologics, Inc. (FBLG)
| Market Cap | 5.75M -83.4% |
| Revenue (ttm) | n/a |
| Net Income | -18.68M |
| EPS | -6.88 |
| Shares Out | 5.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,959 |
| Open | 1.070 |
| Previous Close | 1.050 |
| Day's Range | 1.060 - 1.090 |
| 52-Week Range | 0.952 - 19.800 |
| Beta | 1.18 |
| Analysts | Buy |
| Price Target | 13.50 (+1,167.61%) |
| Earnings Date | Apr 30, 2026 |
About FBLG
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, includi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for FBLG stock is "Buy." The 12-month stock price target is $13.5, which is an increase of 1,167.61% from the latest price.
News
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and suppress key inflammatory pathways associated with chronic psoriatic disease In animal studies, human...
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
HOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development...
FibroBiologics expands fibroblast-based platform to target Hantavirus
FibroBiologics (FBLG) announced a strategic expansion of its fibroblast-based platform to target Hantavirus. Building on existing preclinical work in treating acute respiratory distress syndrome, the ...
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potential Emerging Global Crisis Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated...
FibroBiologics CEO Issues Letter to Shareholders
HOUSTON, May 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the develo...
FibroBiologics Proxy statement: Proxy filing
FibroBiologics filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
FibroBiologics Proxy statement: Proxy filing
FibroBiologics filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
FibroBiologics says fibroblast spheroids drive burn healing, reduce scarring
FibroBiologics (FBLG) announced preclinical results suggesting that topical treatment with human dermal fibroblast spheroids may reprogram the burn wound environment by dampening harmful inflammation,...
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the develo...
FibroBiologics releases first batch of CYWC628 for Phase 1/2 trial
FibroBiologics (FBLG) announced the release of the first batch of its CYWC628 drug product to support its Phase 1/2 clinical trial in patients with diabetic foot ulcers. “With the first…
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the develo...
FibroBiologics downgraded to Hold from Buy at Maxim
Maxim analyst Michael Okunewitch downgraded FibroBiologics (FBLG) to Hold from Buy.
FibroBiologics reports Q1 net loss roughly ($5M)
The net loss for the three months ended March 31, 2026, was primarily due to research and development expenses and general and administrative expenses. Pete O’Heeron, CEO, and Founder of…
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026 On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in...
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the deve...
FibroBiologics Quarterly report: Q1 2026
FibroBiologics has published its Q1 2026 quarterly earnings report on April 30, 2026.
FibroBiologics Earnings release: Q1 2026
FibroBiologics released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
FibroBiologics Proxy statement: Proxy filing
FibroBiologics filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
FibroBiologics announces compliance with all Nasdaq listing requirements
FibroBiologics (FBLG) announced that The Nasdaq Stock Market has confirmed that the company has demonstrated compliance with all applicable criteria for continued listing on The Nasdaq Capital Market,...
FibroBiologics Compliant with All Nasdaq Listing Requirements
HOUSTON, April 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the deve...
FibroBiologics target adjusted to $8 at H.C. Wainwright after reverse split
H.C. Wainwright adjusted the firm’s price target on FibroBiologics (FBLG) to $8 from $4 and keeps a Buy rating on the shares based on the announced 1-for-20 reverse stock split,…
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
Preclinical models demonstrate potential to restore thymic function lost with aging reducing susceptibility to cancer, autoimmune diseases, infections, and reduced vaccine efficacy Preclinical models ...
FibroBiologics Announces Closing of $3 Million Public Offering
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...
FibroBiologics prices $3M public offering
FibroBiologics (FBLG) announced the pricing of a best efforts public offering of an aggregate of 2,272,728 shares of its common stock and warrants to purchase up to 2,272,728 shares of…
FibroBiologics Announces Pricing of $3 Million Public Offering
HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...